香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 石藥創新製藥股份有限公司 截至2025年12月31日止年度之業績預告 按深圳證券交易所之相關規定，石藥集團有限公司（「本公司」）之附屬公司石藥創新製藥股份 有限公司（「石藥創新」，其股份於深圳證券交易所創業板市場上市（ 股票代碼：300765）），已 於2026年1月15日發佈其截至2025年12月31日止年度之業績預告公告（「業績預告公告」）於深 圳證券交易所網站資訊披露頁面http:// www.szse.cn/ disclosure/listed/ notice/index.html。 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記載、誤導 性陳述或重大遺漏。 本公告附錄（「附錄」）所載由石藥創新根據中國企業會計準則編製之業 ...

Core Viewpoint - XinNuoWei (300765) expects a net profit loss of 170 million to 255 million yuan for 2025, compared to a net profit of 53.7263 million yuan in the same period last year [1] Group 1: Financial Performance - The company anticipates a significant decline in net profit for 2025, projecting a loss between 170 million and 255 million yuan [1] - In the previous year, the company reported a net profit of 53.7263 million yuan [1] Group 2: Research and Development Investment - To accelerate the advancement of its innovative pipeline, the company has increased its R&D expenditure to approximately 1 billion yuan for the year, marking a substantial year-on-year increase [1] - The rise in R&D expenses is identified as a key factor impacting the current profit situation [1]

Core Viewpoint - The company, XinNuoWei (300765.SZ), forecasts a net loss attributable to shareholders of 170 million to 255 million yuan for the year 2025, marking a shift from profit to loss year-on-year [1] Group 1: Financial Performance - The company anticipates a significant increase in R&D expenses, projected to reach approximately 1 billion yuan, which is a substantial year-on-year growth and a key factor affecting current profits [1] - The acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotechnology, has increased the company's ownership to 80%, which will amplify the impact of Jushi's losses on the consolidated financial statements [1] Group 2: R&D Progress - During the reporting period, the company made significant advancements in its innovation pipeline, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] - A monoclonal antibody product, Omabuzumab for new indications, has been approved for market launch, while another monoclonal antibody product, Pertuzumab injection, has had its market application accepted [1] - Two ADC products have entered the Phase III clinical stage, reflecting the company's commitment to advancing its research and development efforts [1] Group 3: Functional Raw Materials Business - The company has worked to strengthen its position in the functional raw materials sector, particularly by increasing sales of caffeine products [1] - However, due to market factors, the gross margin and profitability of caffeine products have slightly declined compared to the same period last year, leading to a decrease in profits from the functional raw materials business [1]

Core Viewpoint - The company expects a loss of 170 million to 255 million yuan in 2025, with a non-recurring loss of 210 million to 315 million yuan, primarily due to increased R&D investments to accelerate its innovation pipeline [1] Group 1: Financial Performance - The company anticipates a significant increase in R&D expenses, projected to reach approximately 1 billion yuan, which is a substantial year-on-year growth and a key factor affecting current profits [1] - The company completed the acquisition of an additional 29% minority stake in its subsidiary, Giant Stone Biotechnology, raising its ownership to 80%, which will increase the impact of Giant Stone's losses on the consolidated financial statements [1] Group 2: R&D Progress - During the reporting period, multiple products in the pipeline made significant progress, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] - One monoclonal antibody product (Omarizumab injection) received approval for a new indication, while another monoclonal antibody product (Pertuzumab injection) had its listing application accepted; additionally, two ADC products entered Phase III clinical trials [1] Group 3: Business Operations - The company is actively consolidating its competitive position in the functional raw materials business, particularly by increasing sales of caffeine products [1] - However, due to market factors, the gross margin and profitability of caffeine products slightly declined compared to the same period last year, leading to a decrease in profits from the functional raw materials business [1]

Core Viewpoint - The company expects a loss of 170 million to 255 million yuan in 2025, with a non-recurring loss of 210 million to 315 million yuan, primarily due to increased R&D investments to accelerate innovation pipelines [1] R&D Investments - The company is significantly increasing R&D expenditures, projected to reach approximately 1 billion yuan for the year, marking a substantial year-on-year increase [1] - Multiple products in the pipeline have made significant progress, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] - A monoclonal antibody product (Omalizumab injection) has received approval for a new indication, while another monoclonal antibody product (Pertuzumab injection) has had its listing application accepted [1] - Two ADC products have entered Phase III clinical trials [1] Subsidiary Acquisition - In early November 2025, the company completed the acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotech, increasing its ownership to 80% [1] - Jushi Biotech is currently not profitable due to significant investments in its pipeline, and the increased ownership will amplify its impact on the company's consolidated financial statements [1] Functional Raw Materials Business - The company is actively consolidating its competitive position in the functional raw materials sector, particularly in caffeine products, which have seen increased sales [1] - However, due to market factors, the gross margin and profitability of caffeine products have slightly declined compared to the same period last year, leading to a decrease in profits from the functional raw materials business [1]

（记者 曾健辉） 每经AI快讯，新诺威1月15日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损1.7亿元 ~2.55亿元，同比由盈转亏。业绩变动主要原因是，公司多款在研产品取得重要进展，研发费用投入加 大报告期内，公司为加速推进创新管线，持续加大研发投入。多款在研产品取得重要进展：2025年，公 司4款抗体药物、6款ADC产品及1款mRNA疫苗首次取得临床试验批准；1款单抗产品新适应症获批上 市；1款单抗产品上市申请获得受理；另有2款ADC产品进入III期临床阶段。受上述研发活动推动，全 年研发费用增至约10亿元，同比有较大增长，是影响当期利润的重要因素。 每经头条（nbdtoutiao）——不到20万元，就能买特斯拉了？"廉价版"Model 3或进入中国市场，续航里 程480公里！关于自动驾驶，美国市场也有大调整 ...

新诺威公告，预计2025年度净利润亏损1.7亿元–2.55亿元，上年同期盈利5372.63万元。报告期内，公司 为加速推进创新管线，持续加大研发投入。受上述研发活动推动，全年研发费用增至约10亿元，同比有 较大增长，是影响当期利润的重要因素。 ...

Core Viewpoint - The company, XinNuoWei, is forecasting a significant net loss for the fiscal year 2025, projecting a loss between 170 million to 255 million yuan, contrasting with a profit of 53.73 million yuan in the same period last year [2] Group 1: Financial Performance - The expected net loss for 2025 is between 170 million to 255 million yuan, compared to a profit of 53.73 million yuan in the previous year [2] - The company has increased its R&D expenditure to approximately 1 billion yuan for the year, indicating a substantial year-on-year growth in innovation pipeline investments [2] Group 2: Business Operations - The acquisition of minority stakes in Jushi Bio has contributed to the widening of losses for the company [2] - The functional raw materials business has seen a reduction in profits due to a decline in the gross margin of caffeine-related products [2]

石药创新制药股份有限公司 2025年度业绩预告 证券代码：300765 证券简称：新诺威 公告编号：2026-002 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况：预计净利润为负值 | 项 | 目 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 亏损：17,000万元– | 25,500万元 | 盈利：5,372.63万元 | | | | 比上年同期下降：416% | - 575% | | | 扣除非经常性损 益后的净利润 | | 亏损：21,000万元 – | 31,500万元 | 盈利：4,234.19万元 | | | | 比上年同期下降：596% | - 844% | | 二、与会计师事务所沟通情况 公司已就业绩预告有关事项与会计师事务所进行了预沟通，公 司与会计师事务所在业绩预告方面不存在分歧。 三、业绩变动原因说明 （一）公司多 ...

数据显示，金元顺安基金旗下1只基金重仓新诺威。金元顺安医疗健康混合A类（007861）三季度增持 1.31万股，持有股数4.88万股，占基金净值比例为3.75%，位居第十大重仓股。根据测算，今日浮亏损 失约10.74万元。 金元顺安医疗健康混合A类（007861）成立日期2021年7月29日，最新规模3836.83万。今年以来收益 7.33%，同类排名1797/8840；近一年收益14.79%，同类排名5884/8094；成立以来亏损53.75%。 金元顺安医疗健康混合A类（007861）基金经理为陈铭杰、张海东。 截至发稿，陈铭杰累计任职时间2年82天，现任基金资产总规模7269.52万元，任职期间最佳基金回报 8.68%， 任职期间最差基金回报-24.12%。 张海东累计任职时间144天，现任基金资产总规模6.28亿元，任职期间最佳基金回报5.45%， 任职期间 最差基金回报-1.14%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 1月15日 ...